Aug 13 (Reuters) - Kalaris Therapeutics Inc KLRS.O:
KALARIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
KALARIS THERAPEUTICS INC - CASH & CASH EQUIVALENTS OF $88.4M AS OF JUNE 30, 2025, EXPECTED TO FUND OPERATIONS INTO Q4 2026
KALARIS THERAPEUTICS INC - NET LOSS $11.4M OR $0.61/SHARE IN Q2 2025